Evidence map›Paper›PMID 35063002›Full record

ArticleTrials2022

Effects of traditional Chinese medicine collaborative model (TCMCM) combined with adjuvant chemotherapy on IIIb and IIIc gastric cancer: a protocol for a randomized controlled trial.

Zhaoyan Li, Guangtao Zhang, Nida Cao, Jingjuan Xu, Jiahuan Dong, Jia Li, Xiaohong Zhu, Yan Xu, Chen Han, Rui Wang and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in Trials, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03607656 (The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer), which is not on this map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03607656 phase2 / phase3completednot on this map

The Effect of Traditional Chinese Treatment Combined Adjuvant Chemotherapy in IIIb and IIIc Gastric Cancer: A Randomized Controlled Trial

TypeinterventionalSponsorShanghai University of Traditional Chinese MedicineRan2018 to 2023Enrolled270ConditionsGastric Cancer Stage IIIB, Gastric Cancer Stage IIICArmsOxaliplatin, Capecitabine, TCM, S-1, Docetaxel
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Terpene extract from the stem ofJournal of pharmaceutical analysis · 2024
    Article
  6. Review
  7. Article
  8. Active Ingredients from Chinese Medicine for Combination Cancer Therapy.International journal of biological sciences · 2023
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 1 country.

Zhaoyan Li *Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Guangtao Zhang *Department of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Nida CaoDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Jingjuan XuDepartment of Integrated Traditional and Western Medicine, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, 210002, China.
Jiahuan DongDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Jia LiDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Xiaohong ZhuDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Yan XuDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Chen HanDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Rui WangDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China.
Xiang XiaDepartment of General Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200240, China.
Gang ZhaoDepartment of General Surgery, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200240, China.
Xiangkun HuanDepartment of Digestive tumor surgery, Jiangsu Province Hospital of Chinese Medicine, Nanjing University of Chinese Medicine, Nanjing, 210029, China.
Jin FanDepartment of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Aiguang ZhaoDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine (TCM), 725 Wanping Road, Shanghai, 200032, China. aiguangzhao@qq.com.
Shanghai University of Traditional Chinese Medicine · CNLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNRenji Hospital · CNFudan University Shanghai Cancer Center · CNJiangsu Province Hospital · CNNanjing University · CN

Funding

the Ministry of Science and Technology National Key Research and Development Program 2017YFC1700605
6 · The paper itself

Abstract

backgroundMetastasis and/or recurrence can decrease the survival time of gastric cancer patients undergoing radical operation. Among them, those with stage IIIb and IIIc are especially at a high risk of metastasis and recurrence. The traditional Chinese medicine collaborative model (TCMCM) has been used in the treatment of cancer; however, its effects have not been systematically evaluated. This study is designed to evaluate whether TCMCM can decrease adverse effects after chemotherapy and reduce the recurrence and metastasis of stage IIIb and IIIc gastric cancer. METHODS/

designThis prospective, multicenter, randomized, open-label trial will recruit 260 patients with stage IIIb and IIIc gastric cancer who undergo radical surgery for D2 lymphadenectomy. The patients will be randomly assigned to receive usual adjuvant chemotherapy and TCMCM (intervention group) in a 1:1 ratio. Patients in the intervention group will receive an oral traditional Chinese formula, auricular acupressure, and acupoint therapy. All participants will receive usual adjuvant chemotherapy. The primary outcome is a 3-year disease-free survival rate. Secondary outcomes include quality of life, side effects caused by chemotherapy, and safety-related measures. Assessments will be performed during the screening period, at 4 and 8 cycles after adjuvant chemotherapy, and 9, 12, 18, 24, 30, and 36 months after randomization. Adverse events will be recorded. In addition, biological samples will be collected for mechanism analysis. DISCUSSION: This will be the first clinical trial to evaluate the effects of TCMCM on disease-free survival (DFS) and quality of life in patients with stage IIIb and IIIc gastric cancer. Our results may be used to standardize TCMCM. We will also perform a larger-scale clinical trial in the future.

trial registrationClinicalTrials.gov NCT03607656 . Registered on 1 July 2018. The final protocol version is V1.1.

Indexed as

Stomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantHumansMedicine, Chinese TraditionalMulticenter Studies as TopicProspective StudiesQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeAdjuvant chemotherapyDFSGastric cancerRandomized controlled trialTraditional Chinese medicine collaborative model

Identifiers

PMID35063002
PMCPMC8781354
OpenAlexW4205546184

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.